Functional proteomic analysis reveals the involvement of KIAA1199 in breast cancer growth, motility and invasiveness

BackgroundKIAA1199 is a recently identified novel gene that is up-regulated in human cancer with poor survival. Our proteomic study on signaling polarity in chemotactic cells revealed KIAA1199 as a novel protein target that may be involved in cellular chemotaxis and motility. In the present study, we examined the functional significance of KIAA1199 expression in breast cancer growth, motility and invasiveness.MethodsWe validated the previous microarray observation by tissue microarray immunohistochemistry using a TMA slide containing 12 breast tumor tissue cores and 12 corresponding normal tissues. We performed the shRNA-mediated knockdown of KIAA1199 in MDA-MB-231 and HS578T cells to study the role of this protein in cell proliferation, migration and apoptosis in vitro. We studied the effects of KIAA1199 knockdown in vivo in two groups of mice (n = 5). We carried out the SILAC LC-MS/MS based proteomic studies on the involvement of KIAA1199 in breast cancer.ResultsKIAA1199 mRNA and protein was significantly overexpressed in breast tumor specimens and cell lines as compared with non-neoplastic breast tissues from large-scale microarray and studies of breast cancer cell lines and tumors. To gain deeper insights into the novel role of KIAA1199 in breast cancer, we modulated KIAA1199 expression using shRNA-mediated knockdown in two breast cancer cell lines (MDA-MB-231 and HS578T), expressing higher levels of KIAA1199. The KIAA1199 knockdown cells showed reduced motility and cell proliferation in vitro. Moreover, when the knockdown cells were injected into the mammary fat pads of female athymic nude mice, there was a significant decrease in tumor incidence and growth. In addition, quantitative proteomic analysis revealed that knockdown of KIAA1199 in breast cancer (MDA-MB-231) cells affected a broad range of cellular functions including apoptosis, metabolism and cell motility.ConclusionsOur findings indicate that KIAA1199 may play an important role in breast tumor growth and invasiveness, and that it may represent a novel target for biomarker development and a novel therapeutic target for breast cancer.

[1]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[3]  Shridar Ganesan,et al.  X chromosomal abnormalities in basal-like human breast cancer. , 2006, Cancer cell.

[4]  M. Mumby,et al.  PP2A is required for centromeric localization of Sgo1 and proper chromosome segregation. , 2006, Developmental cell.

[5]  J. Peluso,et al.  Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. , 2008, Endocrinology.

[6]  T. Hunter,et al.  A-Kinase-Anchoring Protein 95 Functions as a Potential Carrier for the Nuclear Translocation of Active Caspase 3 through an Enzyme-Substrate-Like Association , 2005, Molecular and Cellular Biology.

[7]  D. Skalnik,et al.  Identification and Characterization of a Novel Human PP1 Phosphatase Complex* , 2010, The Journal of Biological Chemistry.

[8]  Y. Kawasaki,et al.  Asef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization and are involved in HGF-induced cell migration , 2009, Oncogene.

[9]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[10]  M. Rapé,et al.  Mechanism of Ubiquitin-Chain Formation by the Human Anaphase-Promoting Complex , 2008, Cell.

[11]  T. Ørntoft,et al.  Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells , 2011, British Journal of Cancer.

[12]  J. Schalkwijk,et al.  Interactions of human tenascin-X domains with dermal extracellular matrix molecules , 2006, Archives of Dermatological Research.

[13]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[14]  Xin Huang,et al.  UNiquant, a program for quantitative proteomics analysis using stable isotope labeling. , 2011, Journal of proteome research.

[15]  K. Schulze-Osthoff,et al.  TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21WAF-mediated cell cycle arrest , 2008, Oncogene.

[16]  C. Kostic,et al.  Isolation and characterization of sixteen novel p53 response genes , 2000, Oncogene.

[17]  J. Cowell,et al.  The third member of the transforming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. , 1999, Genomics.

[18]  E. Schmitt,et al.  Characterization of Bax-ς, a Cell Death-Inducing Isoform of Bax , 2000 .

[19]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[20]  E. Schmitt,et al.  Characterization of Bax-sigma, a cell death-inducing isoform of Bax. , 2000, Biochemical and biophysical research communications.

[21]  T. Chittenden,et al.  A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. , 1995, The EMBO journal.

[22]  R. Weinberg,et al.  Chemokine networks and breast cancer metastasis. , 2006, Breast disease.

[23]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[24]  Rong Zeng,et al.  From Proteomic Analysis to Clinical Significance , 2004, Molecular & Cellular Proteomics.

[25]  Carlos García-Estrada,et al.  Proteome Analysis of the Penicillin Producer Penicillium chrysogenum , 2010, Molecular & Cellular Proteomics.

[26]  Arul M. Chinnaiyan,et al.  FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis , 1995, Cell.

[27]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[28]  Izumi Horikawa,et al.  Upregulation of the KIAA1199 gene is associated with cellular mortality. , 2006, Cancer letters.

[29]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[30]  Ronald J Moore,et al.  Profiling signaling polarity in chemotactic cells , 2007, Proceedings of the National Academy of Sciences.

[31]  S. Elmore.  Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[32]  Shiro Suetsugu,et al.  The WASP–WAVE protein network: connecting the membrane to the cytoskeleton , 2007, Nature Reviews Molecular Cell Biology.

[33]  J. Kere,et al.  A novel low-penetrance locus for familial glioma at 15q23-q26.3. , 2002, Cancer research.

[34]  Mingfa Li,et al.  S100A11: Diverse Function and Pathology Corresponding to Different Target Proteins , 2009, Cell Biochemistry and Biophysics.

[35]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[36]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[37]  R. Craven,et al.  Overexpression of the Cytochrome P450 Activator Hpr6 (Heme-1 Domain Protein/Human Progesterone Receptor) in Tumors , 2005, Tumor Biology.

[38]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[39]  Rakesh K. Singh,et al.  Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. , 2006, American journal of clinical pathology.

[40]  S. Cannistra,et al.  BAX protein expression and clinical outcome in epithelial ovarian cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Yusuke Nakamura,et al.  Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters' cells and the fibrocytes, as the cause of nonsyndromic hearing loss , 2003, Journal of Human Genetics.

[42]  K. Mimori,et al.  Clinicopathologic Significance of KIAA1199 Overexpression in Human Gastric Cancer , 2009, Annals of Surgical Oncology.

[43]  L. Hughes,et al.  Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity , 2008, Clinical & Experimental Metastasis.

[44]  C. Martínez-A,et al.  DIO-1 is a gene involved in onset of apoptosis in vitro, whose misexpression disrupts limb development. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Hinrichs,et al.  Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274 , 2011, Journal of Translational Medicine.

[46]  C. Perou,et al.  TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab , 2012, Breast Cancer Research and Treatment.